US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Prescription Drugs: market research reports

RSS Feeds

Prescription Drugs market research reports and industry analysis

  2    4  5  6  7  8  9  10  
Pharmaceuticals and Healthcare Report - Iran Q3 2014
6/18/2014 | published by: Business Monitor International
... the rial means thatwe expect the value of the market to contract sharply in US dollar terms. On a positive note, improvedinternational relations have reduced the political risk associated with operating in the market formultinational ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Philippines Q3 2014
6/18/2014 | published by: Business Monitor International
... with the country's relatively strong economic growth and political stability, will boostpharmaceutical consumption. Headline Expenditure Projections Pharmaceuticals: PHP138.45bn (USD3.20bn) in 2013, rising to PHP143.55bn (USD3.26bn) in 2014;+3.7% in local currency terms and +1.8% in US ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Bahrain Q3 2014
6/18/2014 | published by: Business Monitor International
... a Gulf CooperationCouncil decision to unify the cost of medication in the region and will eventually give rise to cheaperhospital treatments across the country. The demand for medicines will remain driven by the country'sageing population, ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Saudi Arabia Q3 2014
6/18/2014 | published by: Business Monitor International
... as well as make the country amore attractive destination for medical tourisms. More stringent pharmaceutical regulatory policies andincreasing local production will benefit multinational drugmakers' long-term development in the country. Headline Expenditure Projections Pharmaceuticals: SAR22.70bn (USD6.06bn) ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Egypt Q3 2014
6/18/2014 | published by: Business Monitor International
... the past few years. Key challenges facing multinational companies include a restrictive medicine pricing regime, a lack ofregulatory data protection and poor patent enforcement. Domestic companies are meanwhile impaired by aweakened currency, which restricts their ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - India Q3 2014
6/18/2014 | published by: Business Monitor International
... a series of patent disrespect issues. We maintain that low government spending onhealthcare is the root of the problem, as it limits patients' access to services. However, we do not expect thesituation to improve in ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare Report - Uzbekistan Q3 2014
6/18/2014 | published by: Business Monitor International
... However, very littledevelopment of either the pharmaceutical or healthcare sectors can be seen domestically, and we stress thatimprovement to both of these must be made if investors are to see Uzbekistan as a viable opportunity. ...  |  read more...
USD 1,295
Dermatologicals - the Czech Republic
6/16/2014 | published by: Euromonitor International
... of the VAT increase in January 2013 when value-added tax for drugs was increased by one percentage point to 15%. Retailers and distributors in anticipation of the VAT rise had postponed price increases in the ...  |  read more...
USD 900
Pharmaceuticals and Healthcare Report - Belarus Q3 2014
6/11/2014 | published by: Business Monitor International
... escalating trade war with Russia. If Russo-Belarusian relations cannot be patched up, state revenues are set to decline considerably, the net exports deficit will widen significantly and real GDP growth will decline. There are downside ...  |  read more...
USD 1,295
Pharmaceutical Wholesalers (European) - Industry Report
6/10/2014 | published by: Plimsoll Publishing Ltd.
... AVENTIS FRANCE and UNITED DRUG PUBLIC LIMITED COMPANY. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (European) analysis is ideal for anyone ...  |  read more...
USD 1,200
Pharmaceutical Wholesalers (Global) - Industry Report
6/10/2014 | published by: Plimsoll Publishing Ltd.
... HOLDINGS CO., LTD.. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (Global) analysis is ideal for anyone wanting to: See the market ...  |  read more...
USD 1,425
Antobiotic Manufacturers (Global) - Industry Report
6/10/2014 | published by: Plimsoll Publishing Ltd.
... SQUIBB. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Antobiotic Manufacturers (Global) analysis is ideal for anyone wanting to: See the market leaders Identify ...  |  read more...
USD 1,425
Pharma-Patient Engagement: insights from patient opinion leaders
6/10/2014 | published by: FirstWord
... fund more research. So, they are natural bedfellows....? Patient pressure and influence across the range of Pharma's activities is growing. While Patient Advocacy Groups are well established, there is a new breed of patient, empowered ...  |  read more...
USD 495
Pharmaceutical Wholesalers (Nordic) - Industry Report
6/10/2014 | published by: Plimsoll Publishing Ltd.
... AS. This report (compiled in English language) includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (Nordic) analysis is ideal for anyone wanting to: See ...  |  read more...
USD 1,050
Pharmaceuticals and Healthcare : Peru Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... the country due to the lack of a mandatorymedicine pricing system in the country. More stringent quality control, a relatively weak domesticpharmaceutical industry, the ongoing liberalisation of bilateral trade agreements and the healthcare reformas well ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Ukraine Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... region. In 2014, owing to the distressed economicsituation in the country, drugmakers can expect a challenging business environment and capital outflowrestrictions. Import taxes, pricing restrictions, and exchange rate volatility present significant risks todrugmakers operating in ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Belgium Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... highly developed pharmaceutical manufacturing industryis increasingly threatened by cheaper suppliers from Eastern Europe and Asia. Even though percapita spending on pharmaceuticals is relatively high, it is subjected to continual downward pressure, whichtranslates into growth opportunities ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Estonia Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... in pharmaceutical spending in Estonia as theEstonian government's policy of fiscal restraint continues. Fiscal tightening has lead to pressure on theEstonian Health Insurance Fund to rein in pharmaceutical expenditure through pricing limits, genericprescribing and reference ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Brazil Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... improving regulatory regimeand significant private healthcare growth mean that the market presents significant revenue-generatingopportunities for drugmakers and healthcare service providers. However, multinationals will continue toface increasing drug pricing pressure and domestic competition. Headline Expenditure Projections ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : France Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... deficit reduction target of 3.0% of GDP by 2015 - affectingexpenditure on pharmaceuticals and healthcare as a part of the government's fiscal consolidation plans. However, the new government of Manuel Valls has indicated it may ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Colombia Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... cuts. Less stringent bioequivalence regulationswill also undermine sale growth posted by branded generic drugmakers. However, Colombia's relativelyadvanced drug reimbursement system will still offer revenue-generating opportunities for multinationals incomparison with other second-tier Latin American pharmaceutical markets. ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Lebanon Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... accounts for about 90% of Lebanon's hospitals andpharmacies, driving the prescription of high-value pharmaceuticals. However, the government'scommitment to cost containment measures continues as it announces further price reductions for anincreasing selection of medicines, impacting overall ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Argentina Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... in the pharmaceutical industry. The localpharmaceutical market and healthcare system will continue to deteriorate due to insufficient medicinesupply. Domestic inflation in Argentina will continue to erode the competitiveness of its pharmaceuticalexports, minimising gains from a ...  |  read more...
USD 1,295
Pharmaceuticals and Healthcare : Bangladesh Pharmaceuticals and Healthcare Report Q3 2014
6/4/2014 | published by: Business Monitor International
... 10 years, the country will experience morecases of chronic diseases, such as obesity and diabetes. This will translate into a greater demand forinnovative medicines. An end to the TRIPS exemptions will force Bangladeshi drugmakers to ...  |  read more...
USD 1,295
Pharmaceuticals: in Denmark
6/3/2014 | published by: Euromonitor International
... of ibuprofen can no longer be purchased without a prescription. The change was implemented by the Danish Health and Medicines Authority following research published in British Medical Journal, documenting that a ban on OTC sales ...  |  read more...
USD 900
  2    4  5  6  7  8  9  10  
 
Our Clients